INTRODUCTION
Macrophages are heterogeneous and functionally important components of the immune system, and like CD4 + T cells, are key targets of HIV-1 infection. However, HIV-1-infected macrophages are more resistant to virus-mediated cytopathic effects and are not significantly depleted in vivo as opposed to CD4 + T cells (Honeycutt et al., 2016; Stevenson, 2003) . As a result, these cells participate in viral spread and in the establishment and persistence of viral reservoirs in the brain, spleen, lung, gut, and bone marrow (Sattentau and Stevenson, 2016) . Moreover, infection of macrophages may directly promote disease, such as neurological disorders, through mechanisms involving activation of inflammatory processes (DiNapoli et al., 2016) .
Macrophages express HIV-1 receptor CD4 as well as the coreceptors CCR5 and CXCR4 that are required for viral entry (Doms and Trono, 2000) . While CCR5 is the principal co-receptor for virus entry into macrophages, CCR5 usage (R5) per se is not sufficient to predict macrophage tropism (M-tropic) (Cheng-Mayer et al., 1997; Gorry et al., 2001) . Indeed, macrophages express low CD4 (20-fold less) as opposed to CD4 + T cells and are preferentially infected by viruses that encode Env glycoproteins with increased affinity for CD4 or enhanced exposure to CCR5 following CD4 engagement (Arrildt et al., 2015; Joseph et al., 2014; Mefford et al., 2015) . Furthermore, for viruses that do infect macrophages, replication in monocyte-derived macrophages (MDMs) can vary by up to a 1,000-fold (Duncan and Sattentau, 2011) , indicating that subsequent to receptor-mediated fusion, post-entry obstacles exist that must be overcome before infection can be established. For instance, expression of antiviral host factors such as SAMHD1 (Lahouassa et al., 2012) , as well as those that are modulated by chemokines or cytokines including APOBEC3G, TRIM5a, TRIM22, and BST2/Tetherin (Cobos Jimenez et al., 2012) , can influence the levels of productive HIV-1 replication and, consequently, are likely to contribute to this variation.
In addition to antiviral host proteins, recent studies have implicated naturally occurring cellular microRNAs (miRNAs) in modulating MDM susceptibility to HIV-1. For instance, miRNAs that target the 3 0 UTR of HIV-1 transcripts (e.g., miR-28, miR-125b, miR-150, miR-223, and miR-382) are downregulated upon monocyte differentiation into macrophages (Wang et al., 2009) . Several miRNAs are associated with resistance to HIV-1 infection (Swaminathan et al., 2014) : for example, in interferon (IFN)aand IFN-b-activated macrophages where HIV-1 replication is restricted, miR-28, miR-150, miR-223, and miR-382 are upregulated (Cobos Jimenez et al., 2012) . Similarly, miR-155 is upregulated in macrophages treated with Toll-like receptor 3 (TLR3) ligands and targets HIV-dependency factors (HDFs) ADAM10, TNPO3, NUP153, and LEDGF/p75 (Swaminathan et al., 2012) . TLR3 activation in macrophages leads to reduction of these HDFs and decreased HIV-1 infection. Thus, miRNAs are important modulators of macrophage infection by HIV-1 through their action on viral expression and HDFs.
Macrophage phenotype and function vary depending on their location and tissue of origin, and their susceptibility to HIV-1 is also subject to these conditions. Indeed, intestinal macrophages are relatively resistant to HIV-1 infection, whereas vaginal and alveolar macrophages are relatively more susceptible (Jambo et al., 2014; Shen et al., 2011; Shen et al., 2009) . While these different phenotypes can be recapitulated in vitro with MDMs (susceptible) or the M1 or M2 macrophages (pro-or anti-inflammatory; more refractory) (Cassol et al., 2010) , the mechanisms involved in these varying phenotypes are not entirely defined.
Here, we examined the expression profile of over 400 miRNAs in non-HIV-1 producing bystander, productively infected, and uninfected MDMs. Among these miRNAs, we identified miR-221 and miR-222 as two negative regulators of viral receptor CD4, which are upregulated in the bystander cells. Functional analyses of miR-221/miR-222 in macrophages reveal that these two miRNAs, which are efficiently induced by the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-a), represent key host effectors capable of modulating macrophage permissiveness to HIV-1 by inhibiting viral entry via the downregulation of CD4.
RESULTS

miR-221 and miR-222 Are Upregulated in MDMs
Although reports have shown that miRNAs in activated MDMs are associated with restriction of HIV-1 infection (Cobos Jimenez et al., 2012) , the differences in miRNA expression in productively HIV-1-infected and bystander macrophage populations had yet to be investigated. To identify miRNAs that modulate permissiveness to HIV-1 infection, MDMs of 3 blood donors were infected for 6 days with a fully replicative HIV-1 GFP-reporter virus and the miRNA expression profiles of the GFP-negative (Àve) (bystander) and GFP-positive (+ve) cells compared to that of uninfected cells by RNA sequencing (RNA-seq) ( Figure 1 ; Table S1 ). Of the 414 miRNAs analyzed (read value >25), 40 were upregulated and 56 downregulated in GFP+ve MDMs (versus uninfected cells), whereas 56 were increased and 81 reduced in the bystander GFPÀve macrophages (versus uninfected, p < 0.05, Table S1 ). Among the 30 miRNAs with the greatest expression in macrophages (according to the base mean values of Table S1 and as shown in Figure 1A ), miRNAs enhanced in bystander MDMs included miR-28-3p (p = 0.02, log2 = 0.4) and miR-423-3p (p = 0.00027, log2 = 0.76), which have both been reported to target HIV-1 RNAs (Huang et al., 2007; Whisnant et al., 2013) . Although miR-28-3p remained unchanged (log2 = 0.1) in GFP+ve cells (versus mock), miR-423-3p was upregulated in GFP+ve MDMs (p = 0.0063, log2 = 0.57). As with miR-423-3p, miR-155-5p was also enhanced in GFP+ve MDMs (p = 7.6 3 10 À4 , log2 = 0.66) although more pronounced in the bystanders (p = 2.8 3 10 À6 , log2 = 0.92) versus mock ( Figure 1A ; Table S1 ). MiR-155-5p has been shown to downregulate the HDFs LEDGF/p75, ADAM10, and NUP153 in TLR3activated macrophages (Swaminathan et al., 2012) . Downmodulated miRNAs in bystander MDMs included miR-142-5p (p = 0.0026, log2 = À0.687), which has been shown to target SOCS-1 in interleukin (IL)-4/IL-13-treated pro-fibrogenic macrophages (Su et al., 2015) .
Also upregulated in bystander MDMs ( Figure 1A ; Table S1 ) were miR-221-3p (p = 0.001, log2 = 0.6) and miR-222-3p (p = 7.7 3 10 À6 , log2 = 0.87). These two miRNAs (described in Figure 2 ) are derived from a single pri-miRNA precursor and contain the same seed sequence that targets mRNAs (Galardi et al., 2011; Lambeth et al., 2009) ; the fact that both miRNAs were identified in the screen strengthened their potential relevance and justified further analyses. To validate the RNA-seq data, miR-221 and miR-222 in sorted, 6-day HIV-1-infected MDMs were measured by quantitative real-time PCR (real-time qPCR). Both miR-221 and miR-222 are enhanced by $2to 10-fold in GFP-ve bystander MDMs versus uninfected cells ( Figure 1B ) (quantitative analysis revealed that miR-221 and miR-222 were expressed in uninfected MDMs in the range of 3,907 ± 667 and 3,177 ± 555 copies per cell, respectively). This contrasts sharply to miR-186 and miR-151a, which were not modulated in HIV-1 productively infected MDMs or bystanders ( Figure 1B ; Table S1 ). Using a different validation approach, MDMs were infected with a heat stable antigen (HSA)-expressing HIV-1 (encoding BAL Env) and sorted after 36 hr or 6 days of infection. Bystanders had an $2-fold increase in miR-221 or miR-222 (versus mock) after 6 days of infection, and a reduction of both miRNAs was detected in HSA+ve cells ( Figure S1 ). These results show that these miRNAs are clearly enhanced in the bystander MDMs.
CD4 mRNA Is a Target of miR-221 and miR-222 in MDMs We next looked for relevant mRNA targets of miR-221/miR-222 expressed in the monocyte/macrophage lineage. A search using targetscan.org produced several target candidates, p27kip and PUMA being among the best characterized (Lambeth et al., 2009) ; however, among the validated targets identified was CD4, the primary receptor for HIV-1 (Orecchini et al., 2014) . To confirm that CD4 mRNA is a target of miR-221/miR-222, we fused part of the CD4 3 0 UTR harboring the putative miRNA target sequence to the firefly luciferase gene (Luc). Cells transiently expressing this construct were treated with either control or locked nucleic acid (LNA) mimics of miR-221 or miR-222. A 2-fold reduction of Luc activity was detected in cells treated with either miR-221 or miR-222 mimics, versus control-treated cells ( Figure 2 ). This reduction was not found in cells transfected with a Luc-CD4 3 0 UTR fusion in which the miR-221/miR-222 target seed sequence was modified ( Figure 2 ). Finally, CD4 mRNA levels were compared in uninfected and sorted HIV-1-exposed MDM populations; CD4 mRNAs were specifically decreased by $50% in the GFPÀve bystander MDMs ( Figure 2C ). These data suggest that CD4 mRNA is targeted in bystander MDMs by miR-221 and miR-222.
To directly address the impact of miR-221 and miR-222 on CD4 in macrophages, MDMs were transfected with miRNA mimics, and both surface CD4 and mRNA were measured by flow cytometry and real-time qPCR. MDMs treated with mimics of miR-221, miR-222, or a mix of both had less than half CD4 mRNA than control-treated cells, with MDMs treated with both mimics having comparable reduction in CD4 mRNA ( Figure 3A ). MDMs treated with miRNA mimics displayed nearly half the level of CD4 at their surface than the control-treated cells ( Figure 3B ) but did not exhibit any reduction in surface CCR5 expression ( Figure 3C ). Figure S1 and Table S1 .
We also tested if miRNA mimics act on HIV-1 infection of MDMs. Control or miRNA mimic-treated MDMs were infected with modified Luc-encoding HIV-1 viruses coated with either HIV-Env (ADA) or VSV-G, and Luc activity was measured in the cells. HIV-Env or VSV-G pseudotyped HIV particles were used to distinguish between CD4-dependent and independent viral entry. MDMs treated with either miR-221, miR-222 or both mimics showed more than 50% reduction of Luc activity (versus controls) when infected with HIV-1-Env-coated viruses ( Figure 3D ), consistent with the decrease of CD4 at the surface of these MDMs ( Figure 3B ). In contrast, VSV-Gcoated HIV-1 were not affected in miRNA mimic-treated MDMs, excluding that these miRNAs were affecting post entry steps up to transcription through other targets such as p27kip.
THP-1 monocytic cells are reported to undergo a major reduction in surface CD4 expression levels upon phorbol 12-myristate 13-acetate (PMA)-induced differentiation into macrophage-like cells while levels of CCR5 remain unaffected (Konopka and D€ uzg€ unes x, 2002) . Consistent with this sharp decrease in CD4 expression levels, we found that differentiated THP-1 cells displayed a marked reduction of HIV (ADA) entry as compared to HIV (VSV-G) in a single-round replication assay ( Figures S2A and S2B) . Interestingly, we observed that PMA-stimulated THP-1 cells displayed an $10to 15-fold increase in miR-221/miR-222 levels ( Figure S2C ) (quantitative analysis revealed that miR-221 and miR-222 were expressed in undifferentiated THP-1 cells in the range of 15,116 ± 2,263 and 26,670 ± 3,496 copies per cell, respectively). To establish a direct link between CD4 downregulation, miR-221/miR-222 upregulation, and reduced CD4-dependent viral entry, we generated a THP-1 cell line expressing CD4 mRNAs that lack miR-221/miR-222 target sequences (D3 0 CD4 UTR) (THP-1-CD4 R ) ( Figure 2A ) and, as such, cannot be targeted by these miRNAs upon differentiation ( Figure S2D ). Consistently, expression of a CD4 transgene insensitive to miR-221/miR-222 was sufficient to allow efficient HIV (ADA) entry into differentiated THP-1 cells ( Figure S2E ). As previously reported for undifferentiated THP-1 cells (Konopka and D€ uzg€ unes x, 2002) , undifferentiated THP-1-CD4 R were significantly less susceptible to CCR5-tropic (R5) HIV infection.
Overall, these results indicate that miR-221 and miR-222 restrict HIV-1 entry in macrophages by modulating expression of the CD4 receptor. Importantly, the extent of CD4 down-modulation and viral entry restriction appears dependent on miR-221/miR-222 expression levels.
miR-221 and miR-222 Affect HIV-1 Replication in MDMs
To assess the impact of miR-221/miR-222 on HIV-1 replication in macrophages, we used MDMs transfected with both miR-221 and miR-222 antagomirs. Typical transfection efficiency reached 60%-80% (a representative graph is shown in Figure 4A ) using fluorescently labeled antagomirs in similar conditions. MDMs were infected the next day with a fully replicative GFP-expressing HIV-1. Figure 4 shows representative kinetics of virus production (assessed by HIV-1 p24 in the supernatant) and viral spread (as determined by the percentage of GFP+ve cells) in MDMs from 3 blood donors. Analysis of the effect of miR-221/miR-222 antagomirs over several viral replication kinetics (n = 8 replicates from 5 donors) revealed at least a 2-fold enhancement of HIV-1 spread and production at day 12 in the majority of samples analyzed ( Figure 4C ). MDMs from two donors did not respond to miR-221/miR-222 antagomirs initially but MDMs from these same donors were found responsive in subsequent experiments highlighting contextual donor variations (Figures 4B and 4C) . Overall, these results suggest that miR-221/222 limit HIV-1 propagation and production in MDM cultures.
Macrophage Activation by TNF-a Leads to Less CD4 Expression
These findings led us to ask what factor(s) modulate miR-221/ miR-222 in MDMs. If miR-221/miR-222 contribute to bystander MDM resistance to HIV-1 infection, cells could release factors enhancing their expression. A panel of activating pro-and antiinflammatory factors were examined for their effect on CD4 and miR-221/miR-222 expression in MDMs ( Figure S3 ). Macrophage activation increases resistance to HIV-1 replication, mostly by antiviral factors that are mainly acting at post-entry steps (Cassol et al., 2009; Cobos Jimenez et al., 2012; Schlaepfer et al., 2014) . However, a decrease of cell surface CD4 is also a consequence of macrophage activation (Bailer et al., 2000; Herbein et al., 1995; Raposo et al., 2011) . All molecules tested decreased CD4 mRNA albeit to different extents. The most potent molecules tested were lipopolysaccharide (LPS, used as a control), TNF-a, IL-1b, and the TNF-a/IFN-g combination classically used to obtain M1 macrophages; each of these treatments decreased CD4 mRNA and surface CD4 by at least 2-fold as compared to untreated cells ( Figures S3A and S3B ).
We also examined if CD4 downregulation was connected to an increase of miR-221/miR-222 in 48 hr-activated MDMs. Both miR-221 and miR-222 were significantly enhanced by LPS (nearly 30-fold for miR-222; 12-fold for miR-221), or TNF-a (for 10 ng/mL, $10-fold each) but not as much by other cytokines (Figures S3C and S3D ). Although less TNF-a (2 ng/mL, as in the TNF-a/IFN-g combination) resulted in a $2-fold change in miR-221/miR-222 expression, a more important miRNA upregulation was obtained using higher concentrations of TNF-a, thus potentially involving this pathway in miR-221/miR-222 expression.
We then asked if TNF-a-mediated CD4 reduction is directly linked to enhanced expression of miR-221/miR-222 and if miR-221 or miR-222 antagomirs inhibit TNF-a-induced miRNAs. TNF-a (10 ng/mL)-treated MDMs were transfected with antagomirs of miR-221, miR-222, or both, and CD4 mRNA and surface expression determined. As shown previously in Figure S3 , MDMs significantly reduced CD4 mRNA and surface expression by $2-fold following TNF-a activation; however, antagomirs in activated MDMs restored CD4 levels to those in resting macrophages ( Figures 5A and 5B ). Importantly, TNF-a treatment did not affect surface CCR5 expression levels ( Figure 5C ). These data suggest that CD4 decrease in TNF-a-treated macrophages is largely due to miR-221/miR-222 induction. test their impact on HIV-1 entry. This was necessary, as activation of macrophages induces several post-entry blocks (Cassetta et al., 2013; Cobos Jimenez et al., 2012) , making our Luc-encoding HIV-1 virus assay impractical. The fusion assay uses the incorporation of b-lactamase (Blam)-Vpr chimeric molecules into HIV-1 virions and their subsequent delivery into the cytoplasm of target cells following virion fusion. Virus fusion, a process that requires CD4 binding and subsequent co-receptor-mediated HIV-1 Env conformational changes (Wu et al., 1996) , is detected by enzymatic cleavage of a fluorescent substrate of b-lactamase loaded in target cells. We also used the specific fusion inhibitor T20 that competitively binds Env gp41, blocking Env conformational changes within gp41 that are required for viral fusion ( Figure S4A ). Fusion efficiency of Blam-Vpr-containing HIV-1 in TNF-a-treated MDMs is strongly reduced when compared to non-activated cells or to cells infected with a VSV-G coated, CD4-entry independent, HIV-1 (Figures 5D, S4A, and S4B) . Interestingly, when MDMs were transfected with antagomirs of either miR-221, miR-222, or a mix of both following TNF-a activation, HIV-1-mediated fusion was restored to levels comparable to those with the VSV-G-coated controls (Figures 5D and S4B) . These findings suggest that miR-221 or miR-222 antagomirs overcome the reduction of CD4 mediated by TNF-a and re-establish levels of CD4 sufficient to mediate efficient CD4-dependent HIV-1 fusion. Importantly, treatment of differentiated THP-1-CD4 R cells with TNF-a did not affect HIV-1 (ADA) fusion efficiency ( Figure 5E ), suggesting that the potential contribution of other host factors influencing viral fusion to TNF-a-induced restriction is minor. Overall, these results suggest that miR-221/miR-222 contribute to the resistance of TNF-a-activated MDMs to HIV-1 infection by inhibiting HIV-1 entry via CD4.
HIV-1 Infection Enhances TNF-a Secretion in MDMs and
Leads to Increased miR-221/miR-222 Macrophage activation is increased by HIV-1 infection (Cobos-Jimé nez et al., 2011) , and TNF-a is among the cytokines produced in infected MDM cultures (Merrill et al., 1989) . To verify this, we measured the levels of TNF-a in supernatants of infected MDMs studied in the viral replication kinetic assays (Figure 4) . Interestingly, MDMs of donors, which responded efficiently to miR-221/mR-222 antagomirs, released more TNF-a in their supernatants ( Figure 6A ). In another set of experiments, a viruscleared supernatant from an infected macrophage culture (Figure 6B ) was added onto new MDMs. These naive MDMs showed CD4-dependent restricted HIV-1 entry when exposed to HIV-1 ADA Env-coated Luc-encoding viruses ( Figure 6B ). TNF-a is at least partly responsible for this reduction in virus infection because prior treatment of the infected MDM supernatant with neutralizing anti-TNF-a Abs recovered some viral infectivity (versus control antibody-treated supernatant) ( Figure 6B ). To determine if TNF-a in the supernatant of infected MDMs was sufficient to enhance miR-221/miR-222 in macrophages, we measured miRNA expression in the conditioned supernatant-treated MDMs. Both miRNAs were enhanced by $4to 5-fold in supernatant-treated cells, and this increase was totally neutralized by prior addition of anti-TNF-a Abs to the conditioned supernatant ( Figure 6C) suggesting that TNF-a mediates the upregulation of miR-221/miR-222 during HIV-1 infection of MDMs.
MiR-221 Is Enhanced in Myeloid Cells of the Colon as Compared to Blood Myeloid Cells
Taking into account the enhanced miR-221/miR-222 levels in TNF-a-activated MDMs, we compared their expression in macrophages/myeloid cells of different origins to gain a more physiologically relevant perspective. In particular, the gut-associated lymphoid tissue (GALT) has a central role in early HIV-1 infection (Brown and Mattapallil, 2014) , and the gut is rich in macrophages that interact with the local microbiome (Zigmond and Jung, MDMs derived from several blood donors were treated with 10 ng/mL of TNF-a for 24 hr and then transfected with the indicated antagomirs for the following 24 hr. See also Figure S3 . (C) Surface CCR5 was measured by flow cytofluorometry. MFI for each condition is shown for a representative blood donor (n = 4 donors).
(D) MDMs isolated from 4 donors were treated with TNF-a (10 ng/mL) (or not), transfected with the indicated control or antagomirs, and infected with the indicated Blam-Vpr containing viruses. Graph represents mean viral fusion efficiency (%) ± SEM (n = 4 donors). Representative data with cells derived from a blood donor are shown in Figure S4 . (E) Differentiated THP-1-CD4 R cells were treated with TNF-a (10 ng/mL) and infected with the indicated Blam-Vpr containing viruses. The graph represents mean viral fusion efficiency (%) ± SD (n = 3 technical replicates). Statistics in were performed using Student's t test. See also Figures S2, S3 , and S4. 2013). Most myeloid cells in the intestinal mucosa are MDMs (Zigmond and Jung, 2013) , while monocytes are the main myeloid-derived cells in peripheral blood (Ziegler-Heitbrock et al., 2010) . Monocytes are resistant to HIV-1 infection ex vivo, yet they express CD4 and CCR5 and are indeed permissive to HIV-1 entry, indicating that block(s) to HIV-1 infection in these cells occur(s) at post-entry steps (Peng et al., 2007; Triques and Stevenson, 2004) . In contrast, intestinal macrophages are relatively resistant to HIV-1, and it has been suggested that this is due, in part, to lower viral receptor expression (Shen et al., 2011) . Myeloid cells, obtained from matched sigmoid intestine biopsies and peripheral blood of 3 study participants, were sorted by flow cytometry ( Figure 7A) and their miR-221 expression compared ( Figure 7B ). MiR-221 was enhanced in myeloid cells of the colon versus those of peripheral blood, suggesting a potential role of miR-221 in the resistance of intestinal macrophages to HIV-1 infection.
DISCUSSION
Although several groups have investigated the impact of host miRNAs on HIV-1 infection, for example by analyzing their expression in permissive and resistant cells (Cobos Jimenez et al., 2012; Huang et al., 2007; Wang et al., 2009 ), comparing the profile of total HIV-1-infected cell populations with that of uninfected cells remained a hurdle, given that only a small fraction of HIV primary target cells, and particularly macrophages, are truly permissive for HIV-1 infection (Imbeault et al., 2009 ). Thus, data from HIV-1-infected whole MDM populations represent mostly non-productive or uninfected bystander cells. Indeed, depending on their state and origin, macrophages express different levels of host factors, including miRNAs, modulating permissiveness to HIV-1 (Cobos Jimenez et al., 2012) .
To gain true insight into miRNA modulation by HIV-1, we sorted MDMs infected with a HIV-1 encoding GFP into productively infected (GFP+ve) and bystander (GFPÀve) subpopulations prior to RNA-seq analyses. Although expression of the majority of analyzed miRNAs from either GFP+ve or GFPÀve cells did not change versus uninfected cells, we identified several miRNAs in both subpopulations that did change significantly (Figure 1 ; Table S1 ). For instance, miR-142 was downregulated in bystander cells; its target, SOCS-1 (Su et al., 2015) , is a key inhibitor of TLR/nuclear factor kB (NF-kB) signaling and the JAK2/STAT1 pathway (Wilson, 2014) . On the other hand, miRNAs that have been reported to target HIV-1 RNAs (miR-28, miR-423) (Huang et al., 2007; Whisnant et al., 2013) or HDFs (miR-155) (Swaminathan et al., 2012) were accordingly significantly upregulated in bystander MDMs. MiR-28 was also previously shown to be enhanced in IFN-a/IFN-b-activated macrophages and may in part explain the reduced permissiveness of these cells to HIV-1 infection (Cobos Jimenez et al., 2012) . Among the miRNAs with enhanced expression in bystander MDMs were miR-221 and miR-222 ( Figure 1) . These two miRNAs are encoded by a gene on chromosome X as a single pri-miRNA precursor and harbor identical seed sequences that recognize CD4 mRNAs, thus inducing its downregulation (Figure 2) . These results are consistent with a previous report showing that miR-221 and miR-222 target CD4 mRNA (Orecchini et al., 2014) . Our results reveal that ectopic expression of miR-221/miR-222 mimics in human macrophages reduced both CD4 mRNA and cell surface CD4 and led to a specific inhibition of HIV-1 ADA CD4-dependent infection in single-round replication assays (Figure 3) . A role of miR-221/miR-222, as inhibitors of CD4-mediated HIV-1 entry was further demonstrated in the monocytic THP-1 cell line model, which was reported to downregulate CD4 upon PMA-induced differentiation into macrophages (Konopka and D€ uzg€ unes x, 2002) . Our data support a direct role of miR-221/miR-222 in reducing CD4 expression levels and rendering CD4-dependent HIV (ADA) entry inefficient in PMA-stimulated THP-1 cells, which indeed display a marked increase of these miRNAs as compared to undifferentiated THP-1 cells. In fact, introduction of a miR-221/miR-222-resistant CD4 transgene in THP-1 cells allowed effective HIV-1 entry upon differentiation ( Figure S2 ). Using a spreading of infection assay, Konopka and D€ uzg€ unes x, (2002) showed that PMA-stimulated THP-1 cells could support to some degree R5 HIV BAL infection (after 10 days) despite a marked surface CD4 down-modulation. Our results, in contrast, revealed undetectable HIV-1 (ADA) entry using a single-round replication assay. Whether this apparent discrepancy is due to the different assays utilized in the two studies or/and differential properties of the HIV-1 strains (BAL versus ADA) used remains a possibility. In any case, based on our findings, interfering with miR-221/222-mediated CD4 downregulation will enhance the replication kinetics of R5 HIV-1 in differentiated THP-1 cells.
Our data further reveals that miR-221 and miR-222 appear to be part of an antiviral response that limits HIV-1 production and spread during infection of MDMs. Indeed, transfection of miR-221/miR-222 antagomirs prior to HIV-1 infection enhanced viral production and spread by at least 2-fold ( Figure 4) in MDMs of all donors tested, thus highlighting the generality of the observation. Interestingly, having recovered HIV-1-infected MDMs by sorting at two time points enabled us to show that miR-221 and miR-222 increase over time in the bystander population ( Figure S1 ), resulting in enhanced resistance to HIV-1 infection in bystander macrophages via upregulation of miR-221/miR-222 ( Figure 1) .
As previously reported (Herbein et al., 1995 (Herbein et al., , 1996 , we observed a reduction of CD4 in MDMs treated with TNF-a (10 ng/mL) or LPS ( Figure S3 ), both of which activate NF-kBdriven genes, such as that encoding miR-221/miR-222 (Eigsti et al., 2014; Galardi et al., 2011; Liu et al., 2014) . CD4 reduction correlated with induction of miR-221/miR-222 ( Figure S3 ). That CD4 expression following TNF-a treatment is rescued by miR-221/miR-222 antagomir transfection ( Figure 5 ) further establishes that these two miRNAs are the effectors of the CD4 downregulation induced by TNF-a in MDMs. In this context, TNF-a is detected after HIV-1 infection of macrophages in vitro and is present in the plasma and tissues of HIV-1-infected patients (Herbein et al., 1996; Merrill et al., 1989) (Figure 6 ). Addition of conditioned supernatant to naive macrophages ( Figure 6B ) inhibited HIV-1 CD4-mediated entry without affecting downstream virus post-entry steps, and miR-221/miR-222 in supernatant-treated MDMs were enhanced by 4-to 6-fold ( Figure 6C ), both suggesting that TNF-a secreted during HIV-1 infection of macrophages exerts an anti-HIV-1 effect, in part, by down-modulating CD4 expression in bystander cells through miR-221/miR-222 induction. In agreement with this, virus entry is partially rescued by neutralizing anti-TNF-a monoclonal antibodies (mAbs) (Figure 6B) . Such a partial rescue may be due, among others, to the reported presence of RANTES, the CCR5 ligand, in supernatants of HIV-1-infected culture that would also inhibit HIV-1 entry (DeVico and Gallo, 2004) .
M1 macrophages block HIV replication at pre-and post-integration steps and are non-permissive to HIV-1 (Cassetta et al., 2013) . The use of the Blam-Vpr fusion-specific assay (Cavrois et al., 2002) , which does not rely on virus post fusion steps, allowed us to show that part of the blocks to HIV-1 infection induced by TNF-a are taking place at the entry stage ( Figure 5D ), in agreement with previous observations (Herbein et al., 1996) . Importantly, that transfection of miR-221 or miR-222 antagomirs was found to re-establish HIV-1 ADA CD4-dependent fusion in TNF-a-activated MDMs to levels comparable to the HIV-1 VSV-G controls ( Figure 5D ) provides strong evidence that miR-221/miR-222 contribute to the restriction of HIV-1 infection in TNF-a-activated macrophages. Whereas the induction of a 5to 10-fold increase in miR-221/miR-222 expression in non-infected bystander macrophages (Figure 1) or in TNF-a-activated MDMs ( Figure S3 ) had a modulating effect on surface CD4 expression and HIV infection, induction of a 10-to 15-fold enhancement of miR-221/miR-222 during differentiation of THP-1 cells into macrophages had a drastic effect on CD4 expression levels and the susceptibility of these cells to HIV-1 infection ( Figure S2 ). Because the absolute amounts of miR-221/miR-222 were found to differ significantly between resting MDMs and undifferentiated THP-1 cells, these findings suggest that the actual amounts of miR-221/miR-222 present in macrophages and the relative abundance of their target mRNAs will govern the degree of inhibition of CD4-dependent HIV entry.
One defining feature of macrophage-tropic viruses is their ability to infect cells expressing low levels of CD4, a property conferred by the high affinity of their envelope glycoproteins for CD4 (Joseph et al., 2014) . Our results show that a $50% reduction in surface CD4 induced by miR-221/miR-222 results in a significant decrease of HIV entry and spread in TNF-a-exposed macrophages (Figures 4 and 5) . While the biological impact of this reduction may appear disproportionate, studies using CD4and CCR5-inducible Affinofile cell lines have shown that at low CD4 expression range, a condition prevailing in macrophages, small variations in CD4 expression have a disproportionate effect on viral entry by R5 HIV viruses (Johnston et al., 2009; Joseph et al., 2014) . Therefore, inhibition of miR-221-/miR-222-mediated CD4 downregulation with antagomirs over several rounds of viral replication is likely to significantly enhance viral spread and production. Although we cannot completely exclude that TNF-a might upregulate other factors that influence viral entry, our findings using the THP-1 model system suggest that their potential contribution is most probably minor. First, stable expression of a miR-221-/miR-222-resistant CD4 transgene in THP-1 cells was sufficient to renders these cells highly susceptible to HIV entry upon their differentiation into macrophages ( Figure S2 ). Moreover, treatment of differentiated THP-1-CD4 R cells with TNF-a did not affect HIV-1 fusion efficiency ( Figure 5E ).
Overall, our data show that miR-221/miR-222 represent key host effectors that are capable of inhibiting HIV-1 entry in macrophages by downregulating the CD4 receptor. Their expression and activity appear modulated by macrophage activation through pro-inflammatory cytokines, thus providing insight into the mechanisms governing the susceptibility of various populations of macrophages to HIV-1 infection. In this regard, of particular importance is the tissue localization of macrophages with their unique microenvironment: indeed, intestinal macrophages are non-permissive to HIV-1 infection, whereas macrophages isolated from the vagina are more susceptible (Shen et al., 2009) . The non-permissiveness of intestinal macrophages was proposed to result from stromal downregulation of CD4 and CCR5 expression as well as to a post-entry block induced by transforming growth factor b (TGF-b) (Shen et al., 2011) . The fact that miR-221 expression in myeloid cells from colon biopsies is significantly elevated as compared to myeloid cells of the blood (Figure 7) is consistent with the reported reduced CD4 mRNA and surface protein levels in intestinal macrophages. These findings might, in part, explain the lower permissiveness of intestinal macrophages to HIV-1 infection (Shen et al., 2011) . Finally, that miR-221 was found to be among only four miRNAs enhanced in PBMCs from elite controllers and downregulated in PBMCs from viremic progressors (Egañ a-Gorroñ o et al., 2014) further emphasizes the potential relevance of these two miRNAs in HIV-1 infection.
MATERIALS AND METHODS
Study Subjects
Peripheral blood samples and leukocyte-enriched blood by leukapheresis were obtained from HIV-and HCV-seronegative adults (of either gender). Research protocols for the use of human blood cells were approved by the Research Ethics Review Board of the Institut de Recherches Cliniques de Montré al (IRCM). The study using sigmoid intestine biopsies and blood from adult participants received approval from the Institutional Review Board of the McGill University Health Centre and CR-CHUM. All participants had given written informed consent and all studies were in compliance with the Declaration of Helsinki.
Cell Lines, Plasmid Constructs, miRNA Mimics, Antagomirs, Antibodies, and Chemicals All cell lines, including the THP-1-CD4 R cell line, plasmids, miRNA mimics, antagomirs, chemicals, including the T20 fusion inhibitor, as well as procedures used in flow cytometry are described in the Supplemental Experimental Procedures.
MDM Differentiation, Activation, Transfection and HIV-1 Infection
The detailed protocol for monocyte isolation and differentiation into MDMs, MDM characterization and activation, as well as virus production and titers can be found in the Supplemental Experimental Procedures. Transfection of MDMs with either Exiqon miRNA mimics or antagomirs was performed using Lipofectamine RNAimax (Invitrogen). cDNA and appropriate primers (see the Supplemental Experimental Procedures) were added to SybrGreen Select Master Mix (Applied Biosystems) and run on a ViiA96 thermocycler (ThermoFisher Scientific). For miRNA quantitation, primers were designed according to Balcells et al. (2011) . Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control and ddCT variations calculated in all cases.
RNA Extraction
MiRNA 3 0 UTR CD4 Target Validation Assay 293T cells were co-transfected with pGL4.70Actin1.2(8) and either pMIR-REPORTCD4Luciferase or pMIR-REPORTCD4mutLuciferase, treated after 24 hr with controls or mimics of either miR-221, miR-222, or a mix of both and lysed after 24 hr. Luciferase activity was measured using the Dual-Glo Luciferase Assay System (Promega) on a GloMax luminometer (Promega).
Blam-Vpr Fusion Assay
Cells were left untreated (control) or treated with TNF-a for 24 hr and transfected with either control, antagomir miR-221, antagomir miR-222, or a mix of both antagomirs using Lipofectamine RNAimax (Invitrogen). Cells were then infected with Blam-Vpr-containing virus (see the Supplemental Experimental Procedures) at a MOI of 10 for 2 hr in 96-well plates. Following infection, cells were treated as described by Cavrois et al. (2002) and in the Supplemental Experimental Procedures. Viral fusion was determined by comparing the Alexa405 (cleaved CCF2) to the AmCyan (loaded CCF2) channels on a Fortessa flow cytofluorometer.
Analysis of HIV-1 Spread of Infection in MDMs
MDMs were transfected with either control RNA or a mix of both miR-221 and miR-222 LNA antagomirs and cultured for 24 hr in 24-well plates. Cells were then infected with NL4-3ADA-IRES-GFP virus at a MOI of 1, washed, and incubated for 2 weeks. Macrophages and their supernatants were harvested at the indicated time points and viral spread assessed by analyzing the percentage of cells expressing GFP by flow cytometry; virus production was determined by measuring HIV-1 p24 in the supernatants by ELISA (XpressBio). Details about TNF-a measurement in supernatants, processing of conditioned supernatants, and use of conditioned supernatants to treat fresh MDMs can be found in the Supplemental Experimental Procedures.
RNA-Seq of Sorted HIV-1-Infected Macrophage miRNAs and Analysis of miR-221 and miR-222 Expression in HIV-1-Infected Macrophage Populations
For comparative miRNA expression of GFP+ve or GFPÀve versus uninfected (mock) macrophage populations, MDMs (derived from PBMCs of 3 blood donors) were infected with VSV-G-pseudotyped NL4-3ADA-IRES-GFP viruses at an MOI of 1 and cultured for 6 days. GFP+ve and GFPÀve cells were separated using an Influx (BD Biosciences) cell sorter and total RNA extracted. miRNA sequencing was performed by the Illumina TruSeq Small RNA system (Illumina Technologies). Details about bioinformatics processing of sequences can be found in the Supplemental Experimental Procedures.
Comparative Expression of miR-221 in Myeloid Cells Isolated from PBMCs or the Colon Myeloid cells from either peripheral blood or sigmoid intestine biopsies were isolated from 3 adult HIV-negative donors. Cells stained with a cocktail of Abs were suspended in PBS with 5% FBS and 25 mmol/L HEPES buffer, and the myeloid cells-enriched fraction with a CD326 À CD8 À CD19 À CD66b À CD3 À HLA-DR high phenotype was sorted on a BD-FACS Aria III (BD Biosciences). The viability dye LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen), was used to exclude dead cells. Sorted cells were lysed in RLT lysis buffer (Promega) and RNA extracted for miRNA real-time qPCR.
Statistics
Unless specified in the figure legend, all statistical analyses were performed using the non-parametric Mann-Whitney U test. The following symbols were used throughout the manuscript: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
DATA AND SOFTWARE AVAILABILITY
The accession number for the miRNA-seq data reported in this study is GEO: GSE103394. 
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